Canopy Growth Archives - Green Market Report

StaffStaffNovember 9, 2020
Daily-Hit-Header.png

9min950

It’s time for your Daily Hit of cannabis news for November 9, 2020

On the Site

Canopy Growth

Canopy Growth Corporation (NYSE: CGC) reported net revenue of $135.3 million for the second quarter fiscal 2021 ended September 30, 2020, causing the stock to jump in early trading. This was a 77% increase over last year’s fiscal second-quarter revenue of $76.6 million. Still, Canopy delivered a net loss of $96.6 million versus last year’s net income of $242 million for the same time period.

The company also reported a loss per share of ($0.09) which beat the MarketWatch estimate for a loss of ($0.28). The stock was lately trading at $26, an increase of 13%. The company attributed the revenue growth to an increase in Canadian recreational revenue, continued strength in Storz & Bickel vaporizer sales and ThisWorks, and contribution from BioSteel, which was acquired in October 2019 . The net loss was driven by lower other income. Canopy also said that the increase versus the prior year period also benefited from favorable comparison, as Q2 2020 results included a $32.7 million charge for returns, return provisions, and pricing allowances primarily related to restructuring the company’s recreational softgel & oil portfolio.

Tilray

Tilray, Inc. (Nasdaq: TLRY) reported that its total revenue for the third quarter was flat at $51.4 million and up 2.0% sequentially. Net losses fell to  $(2.3) million versus last year’s net loss of $(36.4) million and fell sequentially from $(81.7) million in the second quarter. The most significant driver of the change in net loss during the period was the revaluation of the outstanding warrants associated with the equity offering completed in March. Tilray stock was slightly higher in after-hours trading.

The company attributed the disappointing results on the discontinuation of bulk sales and a slight decrease in Canada medical sales which caused cannabis segment revenue to fall by 11% to $31.4 million. Total cannabis kilogram equivalents sold decreased 53% to 5,107 kilograms from 10,848 kilograms in the prior year’s third quarter. Adult-Use and International Medical sales grew 26% and 42%, respectively. Excluding the year-over-year impact related to bulk sales, total cannabis revenue increased by 24%. Hemp segment revenue increased 28% to $20.0 million (C$26.5 million).

Aurora Cannabis

Canadian-based cannabis company, Aurora Cannabis (NYSE: ACB) reported their Q1 earnings this morning. The results were mixed at best, with shares rising 21% on the potential for cannabis legalization under a Biden administration. Unless otherwise stated, these figures are in Canadian dollars. 

The company’s adjusted gross margin before fair value adjustments on total cannabis net revenue didn’t waver much quarter to quarter, with Aurora Cannabis reporting a 48% adjusted gross margin compared to 50% in Q4 2020. Before fair value adjustments, the company’s adjusted gross margin on cannabis net revenue was 52%. 

Canopy Rivers

Canopy Rivers Inc. (OTC: CNPOF) today released its unaudited condensed interim consolidated financial statements in Canadian dollars and acknowledged taking a $112 million hit for its PharmHouse investment.  The total comprehensive loss for the quarter was $87.0 million. On a positive note, its investment into TerrAscend has appreciated implying an investment value of $214 million.

The company reported that its royalty, interest, and lease income (before provisions for credit losses) was $4.1 million for the quarter. It included income from its various royalty, convertible debenture, and loan agreements, among other items. Other comprehensive income was $23.4 million, net of tax, for the quarter, which included a net increase in the fair value of financial assets of $27.4 million attributed to the positive change in the fair value of the investment in TerrAscend. TerrAscend’s share value increase from $2.87 on June 30, 2020, to $9.75 as of the close of markets on November 6, 2020.

Zynerba

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) reported a net loss of $9 million for the third quarter ending September 30, 2020, with a basic and diluted net loss per share of $(0.31). This beat the Yahoo Finance average analyst estimate for a loss of ($0.43). Six analysts have a Hold rating on the company, while two give it a Buy rating. The company still does not have a revenue-producing drug, but Zynerba said it has enough money until that time comes.

Planet 13

Planet 13 (CSE:PLTH) (OTCQX:PLNHF) is potentially one of the most well-known dispensaries around. They are incredibly innovative, massive in size, and just all around at the top of the dispensary game. Planet 13 is even more special because currently, they’re only located in Las Vegas, Nevada. For having operations in only one state, they sure do gain a ton of attention!

The cannabis megastore just announced their third consecutive month of generating over $7.5 million in revenue. The company’s October revenue clocked out at $7.6 million, with gross margins above 50%. Planet 13’s figures include sales for the SuperStore, as well as Nevada wholesale. 

In Other News

Schultze Special Purpose Acquisition Corp. (NASDAQ: SAMA, SAMAW, and SAMAU) and Clever Leaves International Inc. announced today that they have amended their definitive agreement, which was entered into on July 25, 2020 and is anticipated to become a NASDAQ-listed public company trading under the ticker symbol “CLVR”.

 Under the amended terms, the initial expected enterprise value has been reduced to $206 million from $255 million and the minimum cash condition for SAMA has been reduced to $26 million from $60 million. Additionally, the cash consideration payable to certain Clever Leaves’ shareholders at closing has been amended, thereby increasing the equity rollover consideration of the transaction to approximately 97% while Schultze Special Purpose Acquisition Sponsor, LLC agreed to restructure its’ equity ownership to better align with the capital retained at closing. In connection with these revised terms, institutional investors have committed over $10 million through a private placement to be funded at closing of the Business Combination. Additionally, select SAMA stockholders have agreed not to redeem their shares held thereby providing a path to over $16 million of additional committed capital and thus having adequate capital to consummate the transaction. When including SAMA’s cash in trust, the parties expect to have over $80 million of cash on its balance sheet following closing.

 


Debra BorchardtDebra BorchardtNovember 9, 2020
canopy3-1280x854.jpg

6min1320

Canopy Growth Corporation (NYSE: CGC) reported net revenue of $135.3 million for the second quarter fiscal 2021 ended September 30, 2020, causing the stock to jump in early trading. This was a 77% increase over last year’s fiscal second-quarter revenue of $76.6 million. Still, Canopy delivered a net loss of $96.6 million versus last year’s net income of $242 million for the same time period.

The company also reported a loss per share of ($0.09) which beat the MarketWatch estimate for a loss of ($0.28). The stock was lately trading at $26, an increase of 13%. The company attributed the revenue growth to an increase in Canadian recreational revenue, continued strength in Storz & Bickel vaporizer sales and ThisWorks, and contribution from BioSteel, which was acquired in October 2019 . The net loss was driven by lower other income. Canopy also said that the increase versus the prior year period also benefited from favorable comparison, as Q2 2020 results included a $32.7 million charge for returns, return provisions, and pricing allowances primarily related to restructuring the company’s recreational softgel & oil portfolio.

“Our renewed strategy of winning consumer mindshare, along with increased agility and execution, has resulted in record net revenue for the second quarter and momentum across key areas of business,” said David Klein, CEO.  “Canopy Growth is positioned for continued growth as we establish a strong leadership position that is showcased through our vast portfolio of differentiated brands and products – including our industry-leading cannabis-infused beverages.”

The company’s total SG&A expenses dropped by 19% from last year as the company made cuts in Sales & Marketing and General & Administrative expenses, however, this was offset by higher Research & Development expenses. The 30% drop in sales expenses reflected lower compensation expenses resulting from corporate restructuring actions taken earlier in the year, delayed or canceled marketing activities, and reduced travel-related expenses due to the COVID-19 pandemic. G&A expenses decreased by 26%, while R&D expenses rose by 19% mainly driven by ongoing research studies that commenced after Q2 2020.  Share-based compensation expenses decreased 76% over last year’s second quarter.

“We saw another quarter of improvement in our operating expense ratio while our marketing and R&D investments are being re-directed to drive sales,” added Mike Lee, CFO. “Importantly, our end-to-end review has identified cost savings opportunities in the range of $150 – $200 million across the cost of goods sold, general and administrative expenses, and inventory, and efforts are underway to quickly capture value.  Leveraging ongoing improvements across our business, we are accelerating our path to profitability, notably in our largest market, Canada .”

While cash levels fell, the company is still sitting on top of a mountain of money. The company reported that cash and short-term investments amounted to $1.722 billion on September 30, 2020, representing a decrease of $254 million from $1.976 billion on March 31, 2020, reflecting the EBITDA loss and capital investments.

Beverages

Canopy continues to show its growing strength in the small beverage market for the cannabis industry. The company noted that it has established a leadership position in cannabis-infused beverage segment during the quarter with a 54% dollar share with five Ready-to-Drink  THC cannabis beverages under Tweed, Houseplant, and DeepSpace brands in the Canadian recreational market. “We launched Quatreau RTD CBD beverages across Canada in the current quarter. To date, over 2.0 million beverage units have been shipped since late March 2020.”

Canopy’s BioSteel signed distribution agreements with beverage distribution companies, Reyes Beer Division and Manhattan Beer, alongside several other partnerships through Constellation Brands’ distribution network. “These distribution agreements will bring BioSteel’s ready-to-drink, electrolyte-packed sports hydration beverages to consumers, covering 100% of the US market through direct-store-delivery (DSD) network by early 2021. BioSteel is currently in discussion with several large national accounts and expects to have products on the shelf across Food/Drug/Mass as well as Convenience & Gas channel over the course of the calendar year 2021.”


Debra BorchardtDebra BorchardtOctober 1, 2020
drink-2.jpg

4min3750

Canopy Growth Corporation (NYSE:CGC) and Acreage Holdings, Inc. (OTC: ACRHF, ACRDF) announced today that following the implementation of their amended arrangement, Acreage developed a plan to market Canopy Growth’s THC beverages in the legal adult-use markets in the U.S.

Beginning with Illinois and California in summer 2021, Acreage said it will launch Canopy Growth’s THC beverages into markets as well as in its own dispensaries. Acreage said it will access existing distribution channels through its strategic corporate relationships of both Acreage and Canopy. At this time there are no beverages in the marketplace from the company. The website says that it has “Developed a proprietary process that distills whole flower cannabis into a clear liquid. We are using this liquid as an active ingredient in a wide variety of THC and CBD beverages, offering consumers an alternative to traditional drinks.”

“We have had an incredibly successful introduction into the Canadian cannabis-infused beverage industry with over 1.5 million cans of our THC-infused RTD beverage sold to date,” shared Canopy Growth CEO, David Klein. “We introduced a new product category to cannabis consumers that we knew had the potential to disrupt one of the most mature industries and since launching in Canada, Canopy Growth now owns 5 of the top 6 SKUs in the beverage category with a 74% market share. We are excited for Canopy’s beverages to be introduced to the U.S. market and know from recent BDSA reports that the United States represents a market that achieved roughly $60M in beverage sales in 2019.”

Constellation Brands (NYSE:STZ), which has a big stake in Canopy Growth reported its earnings for the second quarter with revenue falling 3% to $2.26 billion. The losses from its position in in Canopy were $31 million. On a reported basis, earnings for Constellation edged up to $2.76 a share vs. $2.72 a year earlier. Despite bars and restaurants being closed in the U.S. due to the pandemic, the company said that liquor store sales made up for the closures. The pandemic though is causing slowdowns in Mexico.

“We see THC-infused beverages as a game-changer in U.S. cannabis, and we are excited to launch Canopy Growth’s unique beverage offerings to our core markets offering the greatest growth potential next year,” said Bill Van Faasen, Interim CEO of Acreage Holdings. “We are already working on our beverage production capabilities, and look forward to tapping the wealth of experience and research Canopy can offer following its successful entry in the category last year.”

Amended Agreement

Canopy and Acreage recently amended their previous agreement in which Canopy would acquire Acreage once the U.S. legalizes cannabis at the federal level (Triggering Event). The deal was originally valued at $3.4 billion. Instead, Acreage shareholders got an initial up-front payment of $37.5 million in connection with the modification of Canopy Growth’s rights, including the extension of the term, and give Acreage shareholders the ability to participate in upside potential upon the Triggering Event.

There are now Acreage “Fixed” shares and Acreage “Floating” shares which is causing a great deal of confusion amongst investors. The basic gist of the difference is that the fixed shares represent the 70% that Canopy is obligated to buy at .30xx and the floating shares are the 30% they have an option to buy at 30 day vwap or $6.41, whichever is higher.


Kaitlin DomangueKaitlin DomangueAugust 10, 2020
daily_hit004-1280x533.png

1min2760

It’s time for your Daily Hit of cannabis financial news for August 10th, 2020.

On the Site

Canopy Growth Still Reporting Elevated Losses

Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) reported first-quarter fiscal 2021 net revenue increased 22% to $110 million. The net loss of $128 million was lower than last year’s net loss by $66 million which the company attributed to the higher revenue and lower SG&A expenses.

In Other News

Terra Tech Reports Lower Gross Margins as it Becomes Vertically-Integrated 

Former retail-only Terra Tech reported a Q2 revenue of $3.5 million. This is down 26% from the same time last year. The company cites the combined impact of COVID-19 and civil unrest, forcing them to close two of their dispensaries for the entire month of June. Terra Tech reported a gross margin of 42.1% compared to 51.4%, with a net loss of $18.18 million. 


Debra BorchardtDebra BorchardtAugust 10, 2020
canopy3-1280x854.jpg

4min8930

Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) reported first-quarter fiscal 2021 net revenue increased 22% to $110 million. The net loss of $128 million was lower than last year’s net loss by $66 million which the company attributed to the higher revenue and lower SG&A expenses.

“We’re proud of our strong first-quarter performance, despite unprecedented volatility and uncertainty in the market and across the globe,” said David Klein, CEO. “We grew our revenue year-over-year and are seeing market share improvement, notably achieving number one market share in cannabis-infused beverages in the Canadian market.  We are implementing a renewed corporate strategy with the appointment of a new leadership team which will focus on delivering quality products to our consumers, positioning our business for continued growth. The proposed retooled Acreage announcement refocuses our entry for the evolving U.S. market, where we are seeing increased momentum.”

The total SG&A expenses declined by 23% versus last year’s first quarter, driven by year-over-year reductions in Sales & Marketing expenses, partially offset by higher General & Administrative (G&A) and Research & Development (“R&D”) expenses. Canopy said that the sales & marketing expenses decline of 25% reflected lower compensation expenses resulting from corporate restructuring actions taken earlier in the year, delayed or canceled marketing activities, and reduced travel-related expenses due to the COVID-19 pandemic. G&A expenses increased 2%, while R&D expenses rose 61% mainly driven by research studies that commenced in Q2 and Q3 2020 and increased activities to support Cannabis 2.0 product development. Share-based compensation expenses decreased 65% over Q1 2020.

“Following our previously announced restructuring actions, we have substantially reduced our expense and cash burn in this quarter in addition to reducing headcount by over 18% since beginning of this calendar year.  Our marketing and R&D investments are being re-allocated to programs with high-return potential in order to drive sales,” added Mike Lee, CFO. “Our gross margins in the quarter came in below our expectations due to under-utilization of our large-scale infrastructure. We’ve already proven we can deliver a 40%-plus gross margin and are confident that we can return to that level as we work toward higher capacity utilization across our facilities as demand for our cannabis products continue to grow. In the meantime, we are focused on further optimizing our operating footprint through a full end-to-end strategy that looks at people, process, technology, and infrastructure that we believe will lead to best in class margins over time.”

The company also stated that cash and short-term Investments were $2.0 billion at June 30, 2020, unchanged from $2.0 billion at March 31, 2020, reflecting the investment of approximately $245 million by an indirect wholly-owned subsidiary of Constellation Brands (NYSE:STZ) to exercise warrants in the Company offset by the EBITDA loss and capital investments.


StaffStaffJuly 6, 2020
shutterstock_1387048082-scaled.png

8min18661

Editors Note: This is a guest post.

Cannabis and its derivative products are all the rage right now. State after state legalizes its recreational use and dispensaries all over the country are making loads of money. The medicinal aspects of the plant are also heavily taken advantage of by big pharmaceutical companies, with new, branded drugs being released with cannabis as their primary component. 

Although Canada is at the forefront of the legalization battle, having fully legalized all uses of the plant back in October 2018, the United States is not lagging behind. One of the better examples of this in Nevada, where after the passing of a bill allowing the sales of recreational pot by any licensed dispensary, free delivery of cannabis in Las Vegas drew so many customers in, that many of these businesses were running out of drivers! 

These developments naturally make investors around the world question whether investing in cannabis-related stocks is worthwhile. The weed market is very young, and therefore highly volatile, and therefore susceptible to many ups and downs in the nearest future. It will take an additional couple of years for it to stabilize, which is something you need to keep in mind when planning out your investments

The general trend seems to be that it will continue to grow, as proven by the continuous passing of legislation in countries around the world, liberalizing the restrictions on the stuff. This allows entrepreneurs and investors alike to get creative with their money and come up with exciting new ways to consume and make use of cannabis. 

Experts predict that by 2022, the marijuana market will reach $32 billion — that leaves plenty of room for improvement and growth, making weed stocks a perfectly viable option for investments. You will find the most powerful and stable publicly traded cannabis companies below. 

Canopy Growth Corporation

This Canadian company is a true cannabis giant — back in 2014, it became the first company of its kind to be publicly traded. Back then, it was listed on the Toronto stock exchange and made its way to the NYSE in May 2018. Canopy became a go-to store for everyone who wanted to buy cannabis online in Canada

Canopy Growth (NYSE:CGC) made the headlines in 2018 when Constellation Brands bought $4 billion worth of their stock. They are an alcohol importer, so you can be sure that there’s a plan of producing branded marijuana-infused beverages in the works. 

Moreover, Canopy was the first Canadian producer to export their dried marijuana to Germany, making it a truly intercontinental corporation. They continue their operations on European soil through a wholly-owned subsidiary that distributes Canopy products to German pharmacies. 

As of recently, Canopy has been aggressively increasing its footprint in the American market, most notably through striking a deal with Acreage Holdings (a US-based major distributor), allowing it to secure a huge market share in the US, by far the largest cannabis market in the world. 

Canopy Growth is by far the most secure option to invest in, as they have proven their global ambitions and increased scope of their operations year after year since its inception back in 2013. 

Tilray 

Similarly to Canopy, Tilray is also one of the largest cannabis-producing corporations in the world. Based in the United States, its scope is even larger than that of Canopy Growth, with Tilray owning subsidiaries all over the globe — they’re exporting to places like Chile and Argentina, but also plenty of European countries, such as Ireland and Switzerland. Tilray has also opened a licensed production facility in Portugal, the only North American company to produce cannabis-based products in the EU. They can be found in pharmacies in most European countries. 

It is also worth noting that while the Asian cannabis market is largely untapped due to extremely strict regulations of the plant in those regions, Tilray has managed to open up limited facilities in South Korea and Japan — as the trend of cannabis laws being liberalized all over the globe continues onto Asia, Tilray will be ready for it, way ahead of other cannabis enterprises

If you need any more convincing of Tilray’s might and the influence it wields over the global cannabis industry, there is no better example of it than the fact that its CEO, Brendan Kennedy has become the first-ever marijuana billionaire, with his net worth being estimated at around $2.4 billion. 

The Choice is yours 

Investing large amounts of money into a volatile market should always be done with extreme caution. This is a move that needs to be thought through. Should you invest in one of the big boys, like Tilray and Canopy Growth, or move your money towards a smaller, but more exciting enterprise, such as the various local dispensary chains that are literally popping up like mushrooms after heavy rainfall? 

The choice belongs to you. As for the industry giants, it might be more reasonable to buy Canopy Growth stock, as it is still less developed than Tilray, and their potential is still largely untapped, making it the more exciting option of the two. 

 

 


Video StaffVideo StaffJune 26, 2020

6min9431

Happy Pride weekend everyone. Celebrate safely. 

Canopy Growth Corporation (NYSE: CGC) and Acreage Holdings, Inc. (OTCQX: ACRGF) stunned markets when the two companies agreed to an unusual deal in 2019. The agreement was that when cannabis was legalized in the U.S., Canopy would buy Acreage. It was called the “triggering event.” A lot has changed since then and now the deal has changed accordingly.  Acreage shareholders will now get an initial up-front payment of $37.5 million in connection with the modification of Canopy Growth’s rights. That’s a big drop from the original price tag of $3.4 billion.  In addition to that CEO Kevin Murphy is resigning from the company.

Aurora Cannabis Inc.  (NYSE: ACB) is the latest cannabis company to destroy the job argument as a reason for legalization. The Canadian cannabis company laid off 25% of Aurora’s SG&A staff, most of those to take place immediately and a roughly 30% reduction in production staff over the next two quarters. The cuts went to the highest levels including a restructuring of the executive leadership team and the recently announced retirement of President Steve Dobler. Aurora said it has initiated a plan to close operations at five facilities over the next two quarters in order to focus production and manufacturing at the Company’s larger scale and highly efficient sites.

Jushi Holdings Inc. (OTCQX: JUSHF) is planning on buying Vireo Health’s (OTC:VREOF) Pennsylvania Medical Solutions, LLC as the company looks to strengthen its position in the state’s market. Jushi will pay Vireo $16.3 million in cash, a $3.8 million seller note, and assume a $17 million facility associated with a long-term lease obligation. The $37 million deal is expected to close by the end of August 20.

GW Pharmaceuticals plc (Nasdaq: GWPH) said that the UK Home Office has reclassified Epidiolex, the company’s cannabidiol medicine as a Schedule 5 drug. A big relief to patients and pharmacists. 

TILT Holdings Inc. (OTCQB: TLLTF) reported Quarterly revenue of $42.4 million, up 27% Quarter over Quarter and 23% over Q1 2019. The company reported a positive net income of $50,925.  

Organigram Holdings Inc.  (NASDAQ: OGI) issued a very brief announcement stating that the company was facing a lawsuit and that it was changing its newly launched Trailer Park Buds brand. Organigram said it wouldn’t comment on the case, which was started in the Court of Queen’s Bench in Alberta. It is a class-action case that seeks damages from many cannabis companies including Organigram. 

A Cease Trade Orders have been issued by one or more securities commissions. 

Alternate Health Corp.  AHG  Ontario Securities Commission 
Champignon Brands Inc.  SHRM  British Columbia Securities Commission 
CIM International Group Inc.  CIM  Ontario Securities Commission 
iAnthus Capital Holdings Inc.  IAN  Ontario Securities Commission 
Ionic Brands Corp.  IONC  Ontario Securities Commission 
Sunniva Inc.  SNN  Ontario Securities Commission and British Columbia Securities Commission 

Debra BorchardtDebra BorchardtJune 25, 2020
canopy3-1280x854.jpg

9min21330

Canopy Growth Corporation (NYSE: CGC) and Acreage Holdings, Inc. (OTCQX: ACRGF) stunned markets when the two companies agreed to an unusual deal in 2019. The agreement was that when cannabis was legalized in the U.S., Canopy would buy Acreage. It was called the “triggering event” and was originally valued at $3.4 billion. The price has dropped considerably.

A lot has changed since then and now the deal has changed accordingly.  Acreage shareholders will now get an initial up-front payment of $37.5 million in connection with the modification of Canopy Growth’s rights, including the extension of the term, and give Acreage shareholders the ability to participate in upside potential upon the Triggering Event.

In addition to that CEO Kevin Murphy is resigning from the company.

Deal Changes

These are the major changes to the deal as outlined by the companies:

  • Canopy Growth will pay Acreage shareholders and certain convertible security holders an aggregate of $37.5 million (approximately $0.30 per Existing Share on an as-converted basis), with the final amount to be received by each holder determined based on the number of Existing Shares into which all of the eligible securities are convertible at the close of business on the record date for the distribution.
  • Acreage shareholders’ new Fixed Shares, each of which represents 70% of an Existing Share, will be entitled to receive 0.3048 of a Canopy Growth Share, representing a premium of approximately 120% to the June 24, 2020 closing price of the Existing Shares on the Canadian Securities Exchange.
  • Acreage shareholders will be entitled to participate in the long-term value created by Acreage, and in the U.S. cannabis industry generally, as a result of the Floating Shares which Canopy Growth may acquire in the future upon the occurrence or waiver of the Triggering Event at a price based upon the 30-day volume-weighted average trading price of the Floating Shares on the CSE relative to the trading price of the Canopy Growth Shares on the NYSE at that time, subject to a minimum of $6.41 per Floating Share.
  • There will be a creation of two new classes of shares in the capital of Acreage with each existing Acreage subordinate voting share (an “Existing Share”) being converted into 0.7 of a Fixed Share and 0.3 of a Floating Share (with proportionate adjustments for the existing proportionate voting shares and existing multiple voting shares)

CEO Murphy Out

Mr. Murphy has resigned as CEO but will continue to act as Chairman of the board of directors of Acreage and contribute to the strategic direction of the company. He is listed as owning 10% of the company’s stock. Director Bill Van Faasen, former Chairman, CEO, and President of The Blue Cross Blue Shield of Massachusetts will serve as Acreage’s Interim Chief Executive Officer until a permanent replacement has been identified.

“On behalf of the entire Acreage Board, I sincerely thank Kevin for his passion and commitment to building a leading cannabis enterprise across the United States,” said Douglas Maine, Chair of the Acreage Special Committee. “Kevin is a visionary entrepreneur and positioned Acreage for success in the U.S. cannabis industry. As we move forward with a renewed commitment by Canopy Growth and build upon the vision for the U.S., we are optimistic about the long-term growth prospects for our shareholders.”

“I am excited about this New Agreement and the creation of a pre-eminent and truly global cannabis company upon the occurrence of the Triggering Event. I believe the eventual federal permissibility of cannabis in the United States is inevitable and this New Agreement continues to allow our shareholders to become a part of a leading cannabis company following such changes. Moreover, as the largest shareholder of Acreage, I believe this New Arrangement allows all Acreage shareholders to participate in potential upside to their investments through the fixed exchange component of Canopy Growth stock and importantly the new Floating Shares” said Kevin Murphy, Chair of the Acreage Board.

Canopy Loans Acreage $100 Million

In connection with the New Agreement, Canopy Growth has agreed to loan a wholly-owned subsidiary of Acreage (“Acreage Hempco”), up to $100 million pursuant to a secured debenture.  Canopy Growth will loan Acreage Hempco an initial $50 million on and subject to completion of the New Arrangement.  The remaining $50 million will be subject to the satisfaction of certain conditions by Acreage Hempco. The Debenture will bear interest at a rate of 6.1% per annum.

The United States is going to be a core market for Canopy Growth and this New Agreement solidifies our path forward with Acreage,” said David Klein, Chief Executive Officer of Canopy Growth. “I am excited to bring our relationship with Acreage back to center stage in our U.S. strategy and look forward to a time when the laws in the United States permit us to finalize this transaction as we march toward bringing our exciting beverage products to the US.”

Acreage Tumbled Quickly

Eyes were raised recently when Acreage announced that it agreed to a short term loan with an interest rate of 60%. Those terms rattled shareholders. That type of loan is akin to a payday loan and means the company must have really needed the money badly if it was willing to take those terms. The loan is secured by the company’s cannabis operations in Illinois, New Jersey, and Florida, as well as it’s U.S. intellectual property. If it can pay back the loan, In the event of default, the company is further obligated to pay to Lender an additional fee of $6 million.

Acreage was already selling assets and laying off employees after the company overextended itself in trying to become the largest cannabis company in the country. Acreage said it expects to record a pre-tax, non-cash charge of $80 to $100 million in the quarter ending March 31, 2020.

Canopy Growth’s Troubles

While Acreage has been struggling to right its ship, Canopy isn’t in much better shape. The company announced declining revenues and massive losses for the fourth quarter ending March 31, 2020. The net revenue in the quarter dropped by 13% sequentially to $107 million as the company blamed lower Canadian recreational revenue. Canopy Growth also delivered a staggering net loss of $1.3 billion in the quarter which was attributed to impairment and restructuring charges.


Debra BorchardtDebra BorchardtMay 29, 2020
canopy3-1280x854.jpg

5min11360

Canopy Growth Corporation (NYSE: CGC) announced declining revenues and massive losses for the fourth quarter ending March 31, 2020. The net revenue in the quarter dropped by 13% sequentially to $107 million as the company blamed lower Canadian recreational revenue. Canopy Growth also delivered a staggering net loss of $1.3 billion in the quarter which was attributed to impairment and restructuring charges. All numbers are in Canadian dollars.

The stock was falling over 22% in early trading as the company’s GAAP EPS came in at -$3.72 and missed analyst estimates by $3.31.

“Through the COVID-19 pandemic, we have worked hard to ensure the health and well-being of our teams and customers and the continuity of our business.  During this time, our team has rolled out our exciting new cannabis-infused beverages and vape products in Canada and a portfolio of CBD products in the US,” shared CEO David Klein. “True to key priorities that I have outlined for Canopy, we have taken steps to align our capacity with the current market demand and focus our resources against the core markets with the largest and most tangible near-term profit opportunity.”

Guidance Pulled As Company Reboots

Canopy said it will no longer strive to be the first to every market, but strives to the best and become a leading consumer insight and product development company in select priority markets, that matches products and consumer preferences in the cannabis space. The company also said that it expects Fiscal 2021 to be a transition year as it resets its strategic focus, rolls out a new organizational design, and implements a comprehensive operational and supply chain productivity program. Canopy has withdrawn its previously communicated milestones for achieving positive Adjusted EBITDA and Net Income.

Fiscal 2020 Results

The company reported revenue of $398 million for the fiscal year 2020, an increase of 76% over 2019. Unfortunately, the total operating expenses for 2020 were $1.6 billion and the total operating loss for the year was $1.6 billion. The net loss for the year was $1.3 billion.

The basic and diluted loss per share was -$3.80 which was much higher than 2019’s net loss per share of -$2.76.

The company began the year with $2.4 billion in cash and cash equivalents. By the end of 2020, the cash was run down to $1.3 billion. During the last quarter, the company’s free cash flow was a negative $304,725.

New Strategy

The company outlined its new strategy in an earnings statement as follows:

  • Becoming a relentlessly consumer-centric organization by building world-class consumer insights and analytics, coupled with focused, leading-edge R&D and innovation to produce a differentiated product portfolio that will delight consumers. The Company will bring these products to the hands of consumers through best-in-class sales execution;
  • Markets and product categories with the highest and most tangible profit opportunities in the near term. Core markets will be Canada, the US, and Germany with a focus on recreational and medical. To capture future opportunities in emerging markets and categories outside the core, Canopy Growth will deploy an asset-light approach;
  • Driving quality in all aspects of our operation and be positioned to deliver the right product at the right time at the right price from the right facility; and
  • Continuing to lead the industry and set industry standards. This includes spearheading the next phase of the cannabis industry evolution and shaping how the industry evolves. The Company will continue to give back to neighbors and communities through its Grow Good Together initiatives.

Klein added, “I am excited to implement our strategy reset and organization redesign over the course of fiscal 2021.  We have a renewed strategic focus and a clear change agenda that is already underway. We are building what we believe is the best cannabis company in the world by putting the consumer at the heart of everything we do and are re-aligning our organization to be faster and more agile.”


Julie AitchesonJulie AitchesonApril 30, 2020
canopy3-1280x854.jpg

3min6120

April 29th was a challenging day for major marijuana producer, Canopy Growth. In a statement to the Canadian press, Canopy Growth Corporation announced its most recent round of cuts, which saw 200 staff members laid off from Canadian, U.S., and U.K. offices. This brings Canopy Growth’s current layoff total to 1,000 employees, including Covid-19 furloughs. According to reporting by Canadian news outlet OttawaMatters.com, which was present for the briefing, Chief Executive David Klein framed the cuts as Canopy Growth’s shift in focus from being first to being best. This, after a mid-April shake-up in which the company shed 85 full-time workers and closed some facilities. The lay-offs were announced during a group Zoom call, which Kate Dingvall’s reporting for Forbes Magazine revealed lasted only two minutes.

Canopy Growth, which became the first publicly traded cannabis company in North America in April 2014, has built a variety of brands over the years, including Tweed, Spectrum Therapeutics, DNA Genetics, and Maitri. The company struggled to realize a profit due to several factors, including a glut of hemp, slower-than-anticipated development in the Canadian market, changing regulations, and fluctuating demand. The decision to downsize personnel and operations to focus on products that are proven earners with proven demand is Canopy Growth’s latest viability strategy. 

This strategy includes closing two of the company’s largest greenhouses, both in British Columbia, as well as restructuring global operations in Africa, South America, and beyond. Plans for opening a new greenhouse in Ontario were also scrapped, as Canopy shifts the focus of their growing operations from greenhouses to outdoor sites, which are less costly to establish and manage. (These were not permitted by federal regulations until after the company had already invested heavily in greenhouse facilities). Billed as the world’s largest marijuana company, these cutbacks will hardly bump Canopy Growth down to bush league status, but the restructuring of this industry heavyweight is still big news, and will likely have a sizable impact on the cannabis market moving forward.



About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 9 hours

This is a LIMITED Edition hand-painted bowl. Orders must be received by Dec. 12. GMR is excited to announce a coll…

@GreenMarketRpt – 9 hours

The Daily Hit: December 2nd, 2020

Back to Top

You have Successfully Subscribed!